Ehlers-Danlos Syndrome: History and Discovery

The Ehlers-Danlos syndromes (EDS) are a group of inherited connective-tissue disorders — in most subtypes, faults in the body's collagen — that produce loose, hypermobile joints, skin that stretches and tears too easily, and a general fragility of tissues. People recognized the pattern long before they could name its cause: Hippocrates noted unusually lax joints and skin in antiquity, and the "India-rubber men" of nineteenth-century circus sideshows almost certainly had EDS. The eponym honours two early-twentieth-century dermatologists — the Dane Edvard Ehlers, who in 1901 reported a patient with over-stretchy skin, loose joints, and easy bruising, and the Frenchman Henri-Alexandre Danlos, who in 1908 emphasized the skin's fragility and the strange flesh-coloured pseudotumours. Yet the first truly modern description came earlier still, from the Russian dermatologist Chernogubov (Tschernogubow) in 1892. This page traces that tangled story — from sideshow stage to twin namesakes to the genetic classifications of today — and is honest about what is documented, what is attributed, and what, even now, remains unknown.

Table of Contents

  1. What Ehlers-Danlos Syndrome Is
  2. Antiquity: Hippocrates and the First Glimpses
  3. The "India-Rubber Men" of the Sideshow
  4. Chernogubov, 1892: The First Modern Description
  5. Ehlers (1901) and Danlos (1908): The Twin Namesakes
  6. Frederick Parkes Weber and the Naming of the Syndrome
  7. From Villefranche (1997) to the 2017 Classification
  8. The Unsolved Problem: Hypermobile EDS
  9. The Triad: EDS, POTS, and MCAS
  10. Research Papers and References
  11. Connections

What Ehlers-Danlos Syndrome Is

Ehlers-Danlos syndrome is not a single disease but a family of related heritable connective-tissue disorders. Connective tissue is the body's scaffolding and packing material — the collagen-rich framework that gives skin its resilience, holds joints in place, and lends strength to blood-vessel walls, the gut, and internal organs. In most forms of EDS a genetic fault disturbs the structure, production, or processing of collagen (or of the proteins that help build and organize it), so the scaffolding is weaker and more elastic than it should be. The visible result is the classic triad of signs that has been recognized, in one form or another, for well over a century: joints that move beyond the normal range and dislocate easily, skin that stretches further than usual and bruises or splits readily, and a broader fragility of tissues that can affect everything from wound healing to, in the most serious subtypes, the integrity of arteries.

Because collagen is everywhere, EDS can touch nearly every body system, which is exactly why its history is a story of many different specialists — dermatologists, rheumatologists, geneticists, cardiologists — each describing a different facet of the same underlying problem. Understanding what the condition is makes its discovery story easier to follow: the people who first wrote about it were, in effect, each holding a different part of the same elephant, and it took decades of work to recognize that the stretchy skin, the loose joints, and the fragile vessels belonged together.

For the clinical picture, modern subtypes, and management, see the main Ehlers-Danlos Syndrome hub. This page is concerned with how the syndrome came to be seen, described, and named.

Back to Table of Contents

Antiquity: Hippocrates and the First Glimpses

The earliest hints of Ehlers-Danlos syndrome reach back to classical antiquity. Hippocrates, the Greek physician of the fifth and fourth centuries BCE, is widely cited as having noted people with unusually lax joints and loose, slack skin — observations sometimes summarized in the histories of EDS as a description of patients whose joints and skin were abnormally loose, and who bruised or were injured easily. Several historical reviews of the syndrome open with this Hippocratic reference as the first written acknowledgement that some bodies are simply built looser than others.

It is important to read this antecedent carefully and not to over-claim it. Hippocrates did not, and could not, describe "Ehlers-Danlos syndrome" as a defined disorder — the concept of a heritable connective-tissue disease lay more than two thousand years in the future. What the classical record offers is a recognition of the phenotype: that lax joints and stretchy, fragile skin occur and can run in families. That is a genuine and worthwhile observation, and it marks the beginning of the human awareness of these traits, but the link between the ancient note and the modern syndrome is one of resemblance rather than a documented diagnosis.

For most of the centuries that followed, people with these features appear in the record only sporadically and indirectly — as anatomical curiosities, as figures of folklore, and, in the nineteenth century, as performers. The systematic medical story does not truly begin until the very end of the 1800s.

Back to Table of Contents

The "India-Rubber Men" of the Sideshow

In the nineteenth and early twentieth centuries, before the condition had a clinical name, some people with markedly hyperextensible skin found a living on the stage. Billed as the "India-Rubber Man," the "Elastic-Skin Man," or the "India-Rubber-Skin Wonder," they performed in travelling circuses and dime-museum sideshows, where the chief act was to grasp a fold of skin — at the neck, chest, or cheek — and stretch it dramatically far from the body before letting it snap back. Modern medical and historical writers generally agree that many of these performers had Ehlers-Danlos syndrome, whose skin hyperextensibility produces exactly this striking effect.

The best-documented of them is James Morris, an American performer born in the 1800s who toured as the "India-Rubber Man" / "Elastic-Skin Man" and could reportedly pull the skin of his neck up over his face and stretch a fold many inches from his body, apparently without pain. He performed with the Barnum & Bailey circus and, in the late 1890s, was written up in Scientific American as "The Rubber Man" — a sign that the medical and scientific world was beginning to take an interest in these performers as something more than mere curiosities. Other names that recur in sideshow histories include Felix Wehrle and Avery Childs.

Two honest caveats belong here. First, the retrospective diagnosis of historical performers is inference, not proof: we are reading nineteenth-century playbills and photographs through a modern medical lens, and EDS is the most likely explanation for genuine skin-stretchers, but it cannot be confirmed for any individual. Second, not every "India-Rubber Man" was a skin-stretcher at all — some acts under that billing were contortionists exploiting hypermobile joints (which can also reflect EDS) and some were simply double-jointed performers with no disorder. The sideshow era nonetheless matters historically: it put the visible reality of hyperextensible skin in front of a wide public and a curious scientific press in the very decades when physicians were about to describe the condition for the first time.

Back to Table of Contents

Chernogubov, 1892: The First Modern Description

The first genuinely modern medical account of the syndrome was given not by either of its namesakes but by a Russian dermatologist. In 1892, A. N. Chernogubov (his name also transliterated Tschernogubow or Tchernogubow) presented two patients with the combination of skin laxity and fragility together with hypermobility of the large joints to the Moscow Dermatological and Venereologic Society. What makes his report remarkable is not only that it predates Ehlers and Danlos, but that Chernogubov interpreted the findings with striking insight: he proposed that the skin and joint signs both arose from a single underlying defect of the connective tissue throughout the body — essentially the modern understanding, decades early.

The reason Chernogubov is not the household name of the condition is largely one of language and geography. His description was published in Russian and so circulated little in Western European and English-language medicine, where Ehlers and Danlos — writing in the more widely read medical literatures of the following decade — became the names attached to the syndrome. Within the medical literature of the Soviet Union and Russia, by contrast, the condition was long known as Chernogubov's syndrome, and historical reviews now routinely credit him with the priority of first description.

Chernogubov's 1892 account became accessible to English-speaking physicians only much later, when C. W. Denko published a translation and commentary — "Chernogubov's syndrome: a translation of the first modern case report of the Ehlers-Danlos syndrome" — in the Journal of Rheumatology in 1978 (listed in the references below). His story is a recurring lesson in the history of medicine: priority in discovery and priority in naming are not the same thing, and who gets remembered often depends as much on the language a paper is written in as on the quality of the observation.

Back to Table of Contents

Ehlers (1901) and Danlos (1908): The Twin Namesakes

The two physicians whose names the syndrome carries were both dermatologists, working independently, who each described a piece of the picture in the first decade of the twentieth century. Edvard Lauritz Ehlers (1863–1937), a Danish dermatologist in Copenhagen, reported a patient in 1901 who showed the now-classic combination of hyperextensible (over-stretchy) skin, hypermobile joints with a tendency to subluxation, and easy bruising. Ehlers' contribution was to recognize and present these features together as a coherent, distinct clinical entity rather than as unrelated oddities.

Seven years later, in 1908, the French physician Henri-Alexandre Danlos (1844–1912) — a dermatologist with a strong background in the chemistry of skin disease — added the other defining dimension. Commenting on a case, Danlos drew attention to the fragility and over-elasticity of the skin and to the characteristic flesh-coloured pseudotumours (molluscoid lumps that form over pressure points and old injuries), arguing that skin extensibility and fragility were cardinal features of the condition. Where Ehlers had emphasized the joints and the bruising, Danlos sharpened the focus on the skin itself.

Neither man named the syndrome after himself, and neither, at the time, connected his case to Chernogubov's earlier Russian report. Between them, however, Ehlers and Danlos laid out in the widely-read Western literature the core clinical features — stretchy and fragile skin, loose and dislocating joints, easy bruising, and pseudotumours — that would define the disorder for the rest of the twentieth century. It was the combination of their two complementary descriptions that later gave the condition its double-barrelled name.

Back to Table of Contents

Frederick Parkes Weber and the Naming of the Syndrome

The label "Ehlers-Danlos syndrome" did not come from either Ehlers or Danlos. It was proposed by a third physician, the eminent London consultant Frederick Parkes Weber (1863–1962), who is generally credited with bringing the two earlier descriptions together under a single eponym in or around 1936. Parkes Weber — a prolific clinician whose name is attached to several other eponymous conditions — recognized that Ehlers' and Danlos' cases described the same disorder, and he honoured both men by joining their names.

The choice of name is itself a small piece of medical-history irony. The two people memorialized in "Ehlers-Danlos syndrome" were neither the first to describe it (that was Chernogubov, in 1892) nor the one who actually coined the term (that was Parkes Weber, decades later). Each had described only part of the condition. Eponyms are conferred by the community that reads and cites the literature, and in the English- and French-speaking medical world of the early twentieth century it was Ehlers' and Danlos' papers that were known — so their names are the ones that stuck.

Once established, the eponym proved durable, and "Ehlers-Danlos syndrome" has remained the standard name in international use ever since, even as the understanding of what the syndrome is has been transformed by genetics. The name is now firmly a plural — the Ehlers-Danlos syndromes — reflecting the recognition that it covers many distinct disorders rather than one.

Back to Table of Contents

From Villefranche (1997) to the 2017 Classification

For most of the twentieth century EDS was sorted into types by clinical appearance alone, and the number and labelling of those types shifted repeatedly as new families and features were reported. The first major attempt at a unified modern scheme came in the late 1980s (the "Berlin" nosology), but the framework that anchored clinical practice for two decades was the Villefranche nosology, agreed at a 1997 international meeting and published in 1998. Villefranche collapsed the older numbered "types" into six named subtypes — classical, hypermobility, vascular, kyphoscoliosis, arthrochalasia, and dermatosparaxis — and, crucially, began to tie several of them to specific biochemical and genetic defects, such as faults in type V and type III collagen.

Two decades of gene discovery then outgrew that six-type scheme. In 2017, an international consortium published The 2017 International Classification of the Ehlers-Danlos Syndromes (Malfait and colleagues), which expanded the catalogue to thirteen subtypes. The 2017 classification reflects how thoroughly genetics had reshaped the field: for nearly every subtype it names one or more causative genes — defects affecting various collagens and collagen-processing enzymes — and, for those subtypes, a definite diagnosis now rests on identifying the responsible genetic variant rather than on clinical impression alone.

This shift — from describing patterns of stretchy skin and loose joints to naming the precise molecular fault behind each pattern — is the great achievement of the modern era of EDS, and it is the direct descendant of the clinical observations begun by Chernogubov, Ehlers, and Danlos more than a century earlier. The 2017 framework, alongside its accompanying diagnostic criteria and management guidelines, remains the current international standard.

Back to Table of Contents

The Unsolved Problem: Hypermobile EDS

There is one large and important exception to the genetic success story, and intellectual honesty requires that it be stated plainly. Hypermobile EDS (hEDS) — by far the most common form of the syndrome — still has no identified causative gene. Every other subtype in the 2017 classification can, in principle, be confirmed by finding a specific genetic variant; hEDS cannot. It remains the one subtype diagnosed purely on clinical grounds, using the set of criteria laid out alongside the 2017 classification, because there is as yet no molecular test for it.

This is genuinely unusual and genuinely unsolved. The reasons are still being worked out and are the subject of active research: hypermobile EDS may turn out to be genetically heterogeneous (several different underlying causes producing a similar picture), it may involve genes or mechanisms not yet identified, and there is ongoing debate about where its boundaries lie relative to the broader category of hypermobility spectrum disorders. Any specific gene proposed for hEDS should, for now, be regarded as a hypothesis under investigation rather than an established cause — as of this writing, no gene has been confirmed for the hypermobile type.

The contrast is striking: more than 130 years after Chernogubov first proposed that a single connective-tissue defect underlay the skin and joint signs, science has pinned down the molecular cause of the rarer EDS subtypes but not of the commonest one. For the many people living with hEDS, this gap is not academic — it shapes how the condition is diagnosed, how long the path to diagnosis often is, and how it is researched. It is a reminder that the history of Ehlers-Danlos syndrome is still being written.

Back to Table of Contents

The Triad: EDS, POTS, and MCAS

A more recent chapter in the EDS story is the recognition of how often it travels with two other conditions. Clinicians and patients have increasingly described a frequent overlap — sometimes called "the triad" — between hypermobile EDS, postural orthostatic tachycardia syndrome (POTS) (a disorder of the autonomic nervous system in which standing up triggers a steep rise in heart rate, lightheadedness, and fatigue), and mast cell activation syndrome (MCAS) (in which the immune system's mast cells release their chemical signals too readily, causing flushing, hives, gut upset, and reactions to many triggers).

Why these three so often appear together is not yet fully understood, and the relationship should be described with appropriate caution rather than presented as a settled mechanism. Several explanations have been proposed — that fragile connective tissue around blood vessels contributes to the blood-pooling of POTS, that connective-tissue and mast-cell biology are linked, that there is shared genetic susceptibility — but these remain areas of active investigation and some debate. What is well established is the clinical observation: many people with hEDS also meet criteria for POTS, MCAS, or both, and recognizing the cluster can shorten the path to getting all three addressed.

This convergence is, in a sense, the modern echo of Chernogubov's original insight — that seemingly separate symptoms can share a common thread — now extended beyond the connective tissue itself to the autonomic and immune systems that depend on it. The triad is explored in detail, with current evidence and management strategies, in the companion article POTS, MCAS, and the EDS Triad.

Back to Table of Contents

Research Papers and References

The list below pairs key peer-reviewed and historical sources with curated PubMed topic-search links into the history and classification literature of the Ehlers-Danlos syndromes. Where a stable identifier is available it is given as a real DOI or PMID; the remaining entries open a PubMed (National Library of Medicine) topic search in a new tab. The reader should note that several of the early descriptions — including Chernogubov's 1892 presentation and the original papers of Ehlers (1901) and Danlos (1908) — are pre-database historical sources, and the deep antiquity of the Hippocratic note is one of resemblance rather than a documented diagnosis.

  1. Denko CW. Chernogubov's syndrome: a translation of the first modern case report of the Ehlers-Danlos syndrome. Journal of Rheumatology. 1978;5(3):347–352. — PubMed: PMID 372526
  2. Parapia LA, Jackson C. Ehlers-Danlos syndrome — a historical review. British Journal of Haematology. 2008;141(1):32–35. — doi:10.1111/j.1365-2141.2008.06994.x
  3. Malfait F, Francomano C, Byers P, et al. The 2017 International Classification of the Ehlers-Danlos Syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2017;175(1):8–26. — doi:10.1002/ajmg.c.31552
  4. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. American Journal of Medical Genetics. 1998;77(1):31–37. — PubMed: PMID 9557891
  5. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. American Journal of Medical Genetics Part C. 2017;175(1):48–69. — doi:10.1002/ajmg.c.31538
  6. Steinmann B, Royce PM, Superti-Furga A. The Ehlers-Danlos syndrome (historical and clinical overview) — PubMed: Ehlers-Danlos syndrome historical overview
  7. History and eponym of the Ehlers-Danlos syndrome — Ehlers, Danlos, and Tschernogubow — PubMed: Ehlers-Danlos history and eponym
  8. Frederick Parkes Weber and the naming of the Ehlers-Danlos syndrome — PubMed: Parkes Weber and Ehlers-Danlos history
  9. Hypermobile EDS — the search for a causative gene and current genetic uncertainty — PubMed: hypermobile EDS genetics
  10. Collagen biology and the molecular basis of the Ehlers-Danlos syndromes — PubMed: Ehlers-Danlos collagen molecular genetics
  11. The overlap of EDS with POTS and mast cell activation syndrome — PubMed: EDS, POTS, and MCAS overlap
  12. Ehlers-Danlos syndrome in the history of medicine and the "India-rubber" sideshow performers — PubMed: Ehlers-Danlos history (cutis hyperelastica)

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents